Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents

Future Oncology

Volumn 10, Issue 2, 2014, Pages 257-275

  Campisi, Giuseppina ^a   Fedele, Stefano ^b   Fusco, Vittorio ^c   Pizzo, Giuseppe ^a   Di Fede, Olga ^a   Bedogni, Alberto ^d  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c C Arrigo Children's Hospital   (Italy)

^d UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

antiresorptive agents; bisphosphonates; cancer; denosumab; epidemiology; jaw; management; osteonecrosis; risk

Indexed keywords

BONE DENSITY CONSERVATION AGENTS; HUMANS; JAW; NEOPLASMS; OSTEONECROSIS; PROGNOSIS; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 84893820808     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.211     Document Type: Review

References (177)

1. Brown JE, Coleman RE. The present and future role of bisphosphonates in the management of patients with breast cancer. Breast Cancer Res. 4(1), 24-29 (2002). (Pubitemid 34097553)
2. Coleman RE, Mccloskey EV. Bisphosphonates in oncology. Bone 49(1), 71-76 (2011).
3. Peddi P, Lopez-Olivo MA, Pratt GF, Suarez-Almazor ME. Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. Cancer Treat. Rev. 39(1), 97-104 (2013).
4. Coleman RE, Marshall H, Cameron D et al. Breast-cancer adjuvant therapy with zoledronic acid. N. Engl. J. Med. 365(15), 1396-1405 (2011).
5. Gnant M, Mlineritsch B, Stoeger H et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 12(7), 631-641 (2011).
6. Miksad RA, Lai KC, Dodson TB et al. Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw. Oncologist 16(1), 121-132 (2011).
7. Kuhl S, Walter C, Acham S, Pfeffer R, Lambrecht JT. Bisphosphonate- related osteonecrosis of the jaws-a review. Oral Oncol. 48(10), 938-947 (2012).
8. Yarom N, Elad S, Madrid C, Migliorati CA. Osteonecrosis of the jaws induced by drugs other than bisphosphonates-a call to update terminology in light of new data. Oral Oncol. 46(1), e1 (2010).
9. Troeltzsch M, Woodlock T, Kriegelstein S, Steiner T, Messlinger K. Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw. J. Can. Dent. Assoc. 78, c85 (2012).
10. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J. Oral Maxillofac. Surg. 65(3), 369-376 (2007).
11. Fedele S, Porter SR, D'aiuto F et al. Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am. J. Med. 123(11), 1060-1064 (2010).
12. Patel S, Choyee S, Uyanne J et al. Non-exposed bisphosphonate-related osteonecrosis of the jaw: a critical assessment of current definition, staging, and treatment guidelines. Oral Dis. 18(7), 625-632 (2012).
13. Junquera L, Gallego L. Nonexposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant? J. Oral Maxillofac. Surg. 66(7), 1516-1517 (2008). (Pubitemid 351822447)
14. Mawardi H, Treister N, Richardson P et al. Sinus tracts-an early sign of bisphosphonate-associated osteonecrosis of the jaws? J. Oral Maxillofac. Surg. 67(3), 593-601 (2009).
15. Hutchinson M, O'ryan F, Chavez V et al. Radiographic findings in bisphosphonate-treated patients with stage 0 disease in the absence of bone exposure. J. Oral Maxillofac. Surg. 68(9), 2232-2240 (2010).
16. Colella G, Campisi G, Fusco V. American Association of Oral and Maxillofacial Surgeons position paper: Bisphosphonate-Related Osteonecrosis of the Jaws-2009 update: the need to refine the BRONJ definition. J. Oral Maxillofac. Surg. 67(12), 2698-2699 (2009).
17. Yarom N, Fedele S, Lazarovici TS, Elad S. Is exposure of the jawbone mandatory for establishing the diagnosis of bisphosphonate-related osteonecrosis of the jaw? J. Oral Maxillofac. Surg. 68(3), 705 (2010).
18. Mignogna MD, Sadile G, Leuci S. Drugrelated osteonecrosis of the jaws: 'exposure, or not exposure: that is the question'. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 113(5), 704-705 (2012).
19. Truong SV, Chang LC, Berger TG. Bisphosphonate-related osteonecrosis of the jaw presenting as a cutaneous dental sinus tract: a case report and review of the literature. J. Am. Acad. Dermatol. 62(4), 672-676 (2010).
20. Ruggiero SL, Dodson TB, Assael LA et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J. Oral Maxillofac. Surg. 67(5 Suppl.), 2-12 (2009).
21. Khan AA, Sandor GK, Dore E et al. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J. Rheumatol. 35(7), 1391-1397 (2008). (Pubitemid 352000790)
22. Bedogni A, Fusco V, Agrillo A, Campisi G. Learning from experience. Proposal of a refined definition and staging system for bisphosphonate-related osteonecrosis of the jaw (BRONJ). Oral Dis. 18(6), 621-623 (2012).
23. Parameters of Care. Clinical Practice Guidelines for Oral and Maxillofacial Surgery (AAOMS ParCare 2012). J. Oral Maxil. Surg. 70(11), Suppl. 3 (2012).
24. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J. Oral Maxillofac. Surg. 61(9), 1115-1117 (2003). (Pubitemid 37064711)
25. Ruggiero SL, Mehrotra B. Ten years of alendronate treatment for osteoporosis in postmenopausal women. N. Engl. J. Med. 351(2), 190-192; author reply 190-192 (2004). (Pubitemid 38886657)
26. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate- associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 104(1), 83-93 (2005). (Pubitemid 40847755)
27. Migliorati CA. Bisphosphonate-associated oral osteonecrosis. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 99(2), 135 (2005). (Pubitemid 40127185)
28. Migliorati CA, Epstein JB, Abt E, Berenson JR. Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review. Nat. Rev. Endocrinol. 7(1), 34-42 (2011).
29. Solomon DH, Mercer E, Woo SB et al. Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges. Osteoporos Int. 24(1), 237-244 (2013).
30. Migliorati CA, Woo SB, Hewson I et al. A systematic review of bisphosphonate osteonecrosis (BON) in cancer. Support Care Cancer 18(8), 1099-1106 (2010).
31. Zavras AI, Zhu S. Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis? J. Oral Maxillofac. Surg. 64(6), 917-923 (2006).
32. Lapi F, Cipriani F, Caputi AP et al. Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures. Osteoporos Int. 24(2), 697-705 (2013).
33. Kruger TB, Sharikabad MN, Herlofson BB. Bisphosphonate-related osteonecrosis of the jaw in four Nordic countries and an indication of under-reporting. Acta Odontol. Scand. 71(6), 1386-1390 (2013).
34. Fusco V, Galassi C, Berruti A et al. Decreasing frequency of osteonecrosis of the jaw in cancer and myeloma patients treated with bisphosphonates: the experience of the oncology network of piedmont and aosta valley (north-western Italy). ISRN Oncol. 672027(2013) (2013)
35. Morgan GJ, Davies FE, Gregory WM et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 376(9757), 1989-1999 (2010).
36. Coleman R, Woodward E, Brown J et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised Phase III trial (AZURE. BIG 01-04) for women with stage II/III breast cancer. Breast Cancer Res. Treat 127(2), 429-438 (2011).
37. Valachis A, Polyzos NP, Coleman RE et al. Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Oncologist 18(4), 353-361 (2013).
38. Walter C, Al-Nawas B, Grotz KA et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur. Urol. 54(5), 1066-1072 (2008).
39. Ortega C, Montemurro F, Faggiuolo R et al. Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis. Acta Oncol. 46(5), 664-668 (2007). (Pubitemid 46911907)
40. Aragon-Ching JB, Ning YM, Chen CC et al. Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with antiangiogenic agents. Cancer Invest. 27(2), 221-226 (2009).
41. Wadhwa VK, Weston R, Parr NJ. Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer. BJU Int. 105(8), 1082-1088 (2010).
42. Henry DH, Costa L, Goldwasser F et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J. Clin. Oncol. 29(9), 1125-1132 (2011).
43. Fizazi K, Carducci M, Smith M et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377(9768), 813-822 (2011).
44. Smith MR, Saad F, Coleman R et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a Phase 3, randomised, placebo-controlled trial. Lancet 379(9810), 39-46 (2012).
45. Mhaskar R, Redzepovic J, Wheatley K et al. Bisphosphonates in multiple myeloma. Cochrane Database Syst. Rev. 3, CD003188 (2010).
46. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N. Engl. J. Med. 353(1), 99-102; discussion 99-102 (2005).
47. Gimsing P, Carlson K, Turesson I et al. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. Lancet Oncol. 11(10), 973-982 (2010).
48. Corso A, Varettoni M, Zappasodi P et al. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 21(7), 1545-1548 (2007). (Pubitemid 46965296)
49. Saad F, Brown JE, Van Poznak C et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled Phase III trials in cancer patients with bone metastases. Ann. Oncol. 23(5), 1341-1347 (2012).
50. Lipton A, Fizazi K, Stopeck AT et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised. Phase 3 trials. Eur. J. Cancer 48(16), 3082-3092 (2012).
51. Stopeck AT, Lipton A, Body JJ et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol. 28(35), 5132-5139 (2010).
52. Malan J, Ettinger K, Naumann E, Beirne OR. The relationship of denosumab pharmacology and osteonecrosis of the jaws. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 114(6), 671-676 (2012).
53. Bi Y, Gao Y, Ehirchiou D et al. Bisphosphonates cause osteonecrosis of the jaw-like disease in mice. Am. J. Pathol. 177(1), 280-290 (2010).
54. Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J. Oral Maxillofac. Surg. 67(5 Suppl.), 61-70 (2009).
55. Filleul O, Crompot E, Saussez S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J. Cancer Res. Clin. Oncol. 136(8), 1117-1124 (2010).
56. Bedogni A, Blandamura S, Lokmic Z et al. Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 105(3), 358-364 (2008).
57. Campisi G, Lo Russo L, Agrillo A, Vescovi P, Fusco V, Bedogni A. BRONJ expert panel recommendation of the Italian Societies for Maxillofacial Surgery (SICMF) and Oral Pathology and Medicine (SIPMO) on Bisphosphonate-Related Osteonecrosis of the Jaws: risk assessment, preventive strategies and dental management. It. J. Maxillofac. Surg. 22(2), 103-124 (2011).
58. Hoff AO, Toth BB, Altundag K et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J. Bone Miner. Res. 23(6), 826-836 (2008). (Pubitemid 351768801)
59. Vahtsevanos K, Kyrgidis A, Verrou E et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J. Clin. Oncol. 27(32), 5356-5362 (2009).
60. Bamias A, Kastritis E, Bamia C et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J. Clin. Oncol. 23(34), 8580-8587 (2005). (Pubitemid 46211499)
61. Wessel JH, Dodson TB, Zavras AI. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J. Oral Maxillofac. Surg. 66(4), 625-631 (2008). (Pubitemid 351381804)
62. Fusco V, Loidoris A, Colella G, Vescovi P, Campisi G. Osteonecrosis of the jaw (ONJ) risk in breast cancer patients after zoledronic acid treatment. Breast 19(5), 432-433; author reply 433-434 (2010).
63. Kyrgidis A, Vahtsevanos K, Koloutsos G et al. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. J. Clin. Oncol. 26(28), 4634-4638 (2008).
64. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann. Intern. Med. 144(10), 753-761 (2006). (Pubitemid 46780635)
65. Palaska PK, Cartsos V, Zavras AI. Bisphosphonates and time to osteonecrosis development. Oncologist 14(11), 1154-1166 (2009).
66. Badros A, Weikel D, Salama A et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J. Clin. Oncol. 24(6), 945-952 (2006). (Pubitemid 46638849)
67. Dimopoulos MA, Kastritis E, Anagnostopoulos A et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 91(7), 968-971 (2006). (Pubitemid 44023154)
68. Kyle RA, Yee GC, Somerfield MR et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J. Clin. Oncol. 25(17), 2464-2472 (2007). (Pubitemid 46999218)
69. Aapro M, Abrahamsson PA, Body JJ et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann. Oncol. 19(3), 420-432 (2008).
70. Terpos E, Sezer O, Croucher PI et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann. Oncol. 20(8), 1303-1317 (2009).
71. Amadori D, Aglietta M, Alessi B et al. A prospective, randomized trial of zoledronic acid (ZOL; q 4 wk vs q 12 wk) for long-term treatment in patients with bone-metastatic breast cancer (BC) after 1 yr of standard ZOL treatment. J. Clin. Oncol. 30(Suppl.) Abstract 9005 (2012).
72. Jung TI, Hoffmann F, Glaeske G, Felsenberg D. Disease-specific risk for an osteonecrosis of the jaw under bisphosphonate therapy. J. Cancer Res. Clin. Oncol. 136(3), 363-370 (2010).
73. Badros A, Goloubeva O, Terpos E et al. Prevalence and significance of vitamin D deficiency in multiple myeloma patients. Br. J. Haematol. 142(3), 492-494 (2008). (Pubitemid 351962187)
74. Christodoulou C, Pervena A, Klouvas G et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 76(3), 209-211 (2009).
75. Guarneri V, Miles D, Robert N et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res. Treat 122(1), 181-188 (2010).
76. Bozas G, Allgar V, Greenwood F et al. Osteonecrosis of the jaw in patients treated with sunitinib and zoledronic acid. J. Clin. Oncol. 29, Abstract e15182 (2011).
77. Fusco, V Porta C, Paglino C et al. Osteonecrosis of the jaw (ONJ) in patients with renal cancer treated with bisphosphonates (BPs) and sunitinib or other targeted therapy (TT) agents: a multicenter survey. J. Clin. Oncol. 29, Abstract 15182 (2011).
78. Estilo CL, Fornier M, Farooki A et al. Osteonecrosis of the jaw related to bevacizumab. J. Clin. Oncol. 26(24), 4037-4038 (2008).
79. Bettini G, Blandamura S, Saia G, Bedogni A. Bevacizumab-related osteonecrosis of the mandible is a self-limiting disease process. BMJ Case Rep. pii: bcr2012007284 (2012).
80. Otto S, Schreyer C, Hafner S et al. Bisphosphonate-related osteonecrosis of the jaws-characteristics, risk factors, clinical features, localization and impact on oncological treatment. J. Craniomaxillofac. Surg. 40(4), 303-309 (2012).
81. Dimopoulos MA, Kastritis E, Bamia C et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann. Oncol. 20(1), 117-120 (2009).
82. Sarasquete ME, Garcia-Sanz R, Marin L et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 112(7), 2709-2712 (2008).
83. English BC, Baum CE, Adelberg DE et al. A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrateresistant prostate cancer. Ther. Clin. Risk Manag. 6, 579-583 (2010).
84. Marini F, Tonelli P, Cavalli L et al. Pharmacogenetics of bisphosphonateassociated osteonecrosis of the jaw. Front. Biosci. (Elite Ed.) 3, 364-370 (2011).
85. Stockmann P, Nkenke E, Englbrecht M et al. Major histocompatibility complex class II polymorphisms are associated with the development of anti-resorptive agent-induced osteonecrosis of the jaw. J. Craniomaxillofac. Surg. 41(1), 71-75 (2013).
86. Ardine M, Generali D, Donadio M et al. Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw? Ann. Oncol. 17(8), 1336-1337 (2006). (Pubitemid 44288231)
87. Bedogni A, Saia G, Bettini G et al. Osteomalacia: the missing link in the pathogenesis of bisphosphonate-related osteonecrosis of the jaws? Oncologist 17(8), 1114-1119 (2012).
88. Hokugo A, Christensen R, Chung EM et al. Increased prevalence of bisphosphonaterelated osteonecrosis of the jaw with vitamin D deficiency in rats. J. Bone Miner. Res. 25(6), 1337-1349 (2010).
89. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J. Oral Maxillofac. Surg. 63(11), 1567-1575 (2005). (Pubitemid 41525412)
90. Lazarovici TS, Yahalom R, Taicher S et al. Bisphosphonate-related osteonecrosis of the jaw associated with dental implants. J. Oral Maxillofac. Surg. 68(4), 790-796 (2010).
91. Ficarra G, Beninati F, Rubino I et al. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J. Clin. Periodontol.32(11), 1123-1128 (2005). (Pubitemid 41499467)
92. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. (vol 7, pg 508, 2006). Lancet Oncology 7(7), 533-533 (2006).
93. Dodson TB, Raje NS, Caruso PA, Rosenberg AE. Case records of the Massachusetts General Hospital. Case 9-2008. A 65-yearold woman with a nonhealing ulcer of the jaw. N. Engl. J. Med. 358(12), 1283-1291 (2008).
94. Palomo L, Bissada N, Liu J. Bisphosphonate therapy for bone loss in patients with osteoporosis and periodontal disease: clinical perspectives and review of the literature. Quintessence Int. 37(2), 103-107 (2006). (Pubitemid 43129192)
95. Position paper: epidemiology of periodontal diseases. American Academy of Periodontology. J. Periodontol. 67(9), 935-945 (1996).
96. Parameter on periodontal maintenance. American Academy of Periodontology. J. Periodontol. 71(5 Suppl.), 849-850 (2000).
97. Tezal M, Wactawski-Wende J, Grossi SG, Dmochowski J, Genco RJ. Periodontal disease and the incidence of tooth loss in postmenopausal women. J. Periodontol. 76(7), 1123-1128 (2005). (Pubitemid 41065402)
98. Renvert S, Persson GR. Supportive periodontal therapy. Periodontology 2000 36, 179-195 (2004). (Pubitemid 41694994)
99. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J. Oral Maxillofac. Surg. 62(5), 527-534 (2004). (Pubitemid 38542516)
100. Ferlito S, Puzzo S, Liardo C. Preventive protocol for tooth extractions in patients treated with zoledronate: a case series. YJOMS 69(6), e1-e4 (2011).
101. Bedogni A, Fusco V, Scoletta M et al. Adding imaging to the clinical picture improves BRONJ case adjudication and staging classification: results of the 'MISSION' study. Eur. J. Cancer 49(Suppl. 2), S154-S297 (2013).
102. Malan J, Ettinger K, Naumann E, Beirne OR. The relationship of denosumab pharmacology and osteonecrosis of the jaws. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 114(6), 671-676 (2012).
103. Vescovi P, Merigo E, Meleti M et al. Bisphosphonates-related osteonecrosis of the jaws: a concise review of the literature and a report of a single-centre experience with 151 patients. J. Oral Pathol. Med. 41(3), 214-221 (2012).
104. Urade M, Tanaka N, Furusawa K et al. Nationwide survey for bisphosphonate-related osteonecrosis of the jaws in Japan. J. Oral Maxil. Surg. 69(11), e364-e371 (2011).
105. Graziani F, Vescovi P, Campisi G et al. Resective surgical approach shows a high performance in the management of advanced cases of bisphosphonate- related osteonecrosis of the jaws: a retrospective survey of 347 cases. J. Oral Maxil. Surg. 70(11), 2501-2507 (2012).
106. Holzinger D, Seemann R, Klug C et al. Long-term success of surgery in bisphosphonate-related osteonecrosis of the jaws (BRONJs). Oral Oncol. 49(1), 66-70 (2013).
107. Lazarovici TS, Yahalom R, Taicher S et al. Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients. J. Oral Maxillofac. Surg. 67(4), 850-855 (2009).
108. Scoletta M, Arduino PG, Dalmasso P, Broccoletti R, Mozzati M. Treatment outcomes in patients with bisphosphonaterelated osteonecrosis of the jaws: a prospective study. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 110(1), 46-53 (2010).
109. Wutzl A, Biedermann E, Wanschitz F et al. Treatment results of bisphosphonate-related osteonecrosis of the jaws. Head Neck 30(9), 1224-1230 (2008).
110. Nicolatou-Galitis O, Papadopoulou E, Sarri T et al. Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 112(2), 195-202 (2011).
111. Bedogni A, Saia G, Bettini G et al. Long-term outcomes of surgical resection of the jaws in cancer patients with bisphosphonate-related osteonecrosis. Oral Oncol. 47(5), 420-424 (2011).
112. Van Den Wyngaert T, Claeys T, Huizing MT, Vermorken JB, Fossion E. Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome. Ann. Oncol. 20(2), 331-336 (2009).
113. O'Ryan FS, Lo JC. Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes. J. Oral Maxillofac. Surg. 70(8), 1844-1853 (2012).
114. Fortuna G, Ruoppo E, Pollio A et al. Multiple myeloma vs. breast cancer patients with bisphosphonates-related osteonecrosis of the jaws: a comparative analysis of response to treatment and predictors of outcome. J. Oral Pathol. Med. 41(3), 222-228 (2012).
115. Badros A, Terpos E, Katodritou E et al. Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J. Clin. Oncol. 26(36), 5904-5909 (2008).
116. Moretti F, Pelliccioni GA, Montebugnoli L, Marchetti C. A prospective clinical trial for assessing the efficacy of a minimally invasive protocol in patients with bisphosphonateassociated osteonecrosis of the jaws. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 112(6), 777-782 (2011).
117. Ripamonti CI, Maniezzo M, Campa T et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann. Oncol. 20(1), 137-145 (2009).
118. Bonacina R, Mariani U, Villa F, Villa A. Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients. J. Can. Dent. Assoc. 77, b147 (2011).
119. Lopez-Jornet P, Camacho-Alonso F, Molina-Minano F, Gomez-Garcia F. Bisphosphonateassociated osteonecrosis of the jaw. Knowledge and attitudes of dentists and dental students: a preliminary study. J. Eval. Clin. Pract. 16(5), 878-882 (2010).
120. Migliorati CA, Mattos K, Palazzolo MJ. How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care. J. Am. Dent. Assoc. 141(5), 562-566 (2010).
121. Diz P, Lopez-Cedrun JL, Arenaz J, Scully C. Denosumab-related osteonecrosis of the jaw. J. Am. Dent. Assoc. 143(9), 981-984 (2012).
122. Migliorati CA, Hsu CJ, Chopra S, Kaltman SS. Dental management of patients with a history of bisphosphonate therapy: clinical dilemma. 36(10), 769-774 (2008).
123. Campisi G, Di Fede O, Musciotto A et al. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): run dental management designs and issues in diagnosis. Ann. Oncol. 18(Suppl. 6), vi168-172 (2007).
124. Saia G, Blandamura S, Bettini G et al. Occurrence of bisphosphonate- related osteonecrosis of the jaw after surgical tooth extraction. J. Oral Maxillofac. Surg. 68(4), 797-804 (2010).
125. Lodi G, Sardella A, Salis A et al. Tooth extraction in patients taking intravenous bisphosphonates: a preventive protocol and case series. J. Oral Maxillofac. Surg. 68(1), 107-110 (2010).
126. Scoletta M, Arata V, Arduino PG et al. Tooth extractions in intravenous bisphosphonatetreated patients: a refined protocol. J. Oral Maxillofac. Surg. 71(6), 994-999 (2013).
127. Berenson JR, Rajdev L, Broder M. Treatment strategies for skeletal complications of cancer. Cancer Biol. Ther. 5(9), 1074-1077 (2006). (Pubitemid 44772213)
128. Reid IR. Bisphosphonates. Skeletal Radiol. 36(8), 711-714 (2007). (Pubitemid 47009815)
129. Corrado A, Cantatore FP. [The bisphosponates: chemical characteristics, skeletal biological effects and extra-skeletal effects]. Reumatismo 57(3), 142-153 (2005). (Pubitemid 41441650)
130. Landesberg R, Cozin M, Cremers S et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J. Oral Maxillofac. Surg. 66(5), 839-847 (2008). (Pubitemid 351522817)
131. Ruggiero SL. Emerging concepts in the management and treatment of osteonecrosis of the jaw. Oral Maxillofac. Surg. Clin. North Am. 25(1), 11-20 (2013).
132. Raccomandazioni Clinico-Terapeutiche su Osteonecrosi Delle Ossa Mascellari Associata a Bisfosfonati e Sua Prevenzione (Version 1.1). Cleup, Padova, Italy (In Press) (2013).
133. Yoneda T, Hagino H, Sugimoto T et al. Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J. Bone Miner. Metab. 28(4), 365-383 (2010).
134. Yamashita J, Mccauley LK. Antiresorptives and osteonecrosis of the jaw. J. Evid. Based Dent. Pract. 12(3 Suppl.), 233-247 (2012).
135. Raber-Durlacher JE, Elad S, Barasch A. Oral mucositis. Oral Oncol. 46(6), 452-456 (2010).
136. Harper RP, Fung E. Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J. Oral Maxillofac. Surg. 65(3), 573-580 (2007). (Pubitemid 46343587)
137. Narongroeknawin P, Danila MI, Humphreys LG, Jr., Barasch A, Curtis JR. Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: a review of the literature and a case report. Spec. Care Dentist 30(2), 77-82 (2010).
138. Lau AN, Adachi JD. Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1-34)] therapy. J. Rheumatol. 36(8), 1835-1837 (2009).
139. Cheung A, Seeman E. Teriparatide therapy for alendronate-associated osteonecrosis of the jaw. N. Engl. J. Med. 363(25), 2473-2474 (2010).
140. Freiberger JJ, Padilla-Burgos R, Chhoeu AH et al. Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series. J. Oral Maxillofac. Surg. 65(7), 1321-1327 (2007). (Pubitemid 46907400)
141. Spiegelberg L, Djasim UM, Van Neck HW, Wolvius EB, Van Der Wal KG. Hyperbaric oxygen therapy in the management of radiation-induced injury in the head and neck region: a review of the literature. J. Oral Maxillofac. Surg. 68(8), 1732-1739 (2010).
142. The Clinical and Cost Effectiveness of Hyperbaric Oxygen Therapy. HTA Systematic Review 2. NHS Quality Improvement Scotland, Edinburgh, Scotland (2008).
143. Ripamonti CI, Cislaghi E, Mariani L, Maniezzo M. Efficacy and safety of medical ozone (O(3)) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: preliminary results of a Phase I-II study. Oral Oncol. 47(3), 185-190 (2011).
144. Agrillo A, Filiaci F, Ramieri V et al. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): 5 year experience in the treatment of 131 cases with ozone therapy. Eur. Rev. Med. Pharmacol. Sci. 16(12), 1741-1747 (2012).
145. Bagan J, Blade J, Cozar JM et al. Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. Med. Oral Patol. Oral Cir. Bucal. 12(4), e336-e340 (2007).
146. Hellstein JW, Adler RA, Edwards B et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J. Am. Dent. Assoc. 142(11), 1243-1251 (2011).
147. Ruggiero SL, Woo SB. Biophosphonate-related osteonecrosis of the jaws. Dent. Clin. N. Am. 52(1), 111-128, ix (2008).
148. Reid IR. Osteonecrosis of the jaw: who gets it, and why? Bone 44(1), 4-10 (2009).
149. Magopoulos C, Karakinaris G, Telioudis Z et al. Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment proposals. Am. J. Otolaryngol. 28(3), 158-163 (2007). (Pubitemid 46702356)
150. Cremers S, Farooki A. Biochemical markers of bone turnover in osteonecrosis of the jaw in patients with osteoporosis and advanced cancer involving the bone. Ann. NY Acad. Sci. 1218, 80-87 (2011).
151. Mcclung M, Harris ST, Miller PD et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am. J. Med. 126(1), 13-20 (2013).
152. Brozoski MA, Traina AA, Deboni MC, Marques MM, Naclerio-Homem Mda G. Bisphosphonate-related osteonecrosis of the jaw. Rev. Bras. Reumatol. 52(2), 265-270 (2012).
153. Otto S, Hafner S, Mast G et al. Bisphosphonate-related osteonecrosis of
154. Tubiana-Hulin M, Spielmann M, Roux C et al. Physiopathology and management of osteonecrosis of the jaws related to bisphosphonate therapy for malignant bone lesions. A French expert panel analysis. Crit. Rev. Oncol. Hematol. 71(1), 12-21 (2009).
155. Cheng A, Mavrokokki A, Carter G et al. The dental implications of bisphosphonates and bone disease. Aust. Dent. J. 50(4 Suppl. 2), S4-S13 (2005). (Pubitemid 43074661)
156. Greenberg MS. Intravenous bisphosphonates and osteonecrosis. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 98(3), 259-260 (2004). (Pubitemid 39200690)
157. Mucke T, Haarmann S, Wolff KD, Holzle F. Bisphosphonate related osteonecrosis of the jaws treated by surgical resection and immediate osseous microvascular reconstruction. J. Craniomaxillofac. Surg. 37(5), 291-297 (2009).
158. Carlson ER, Basile JD. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. J. Oral Maxillofac. Surg. 67(5 Suppl.), 85-95 (2009).
159. Stockmann P, Vairaktaris E, Wehrhan F et al. Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up. Support Care Cancer 18(4), 449-460 (2010).
160. Williamson RA. Surgical management of bisphosphonate induced osteonecrosis of the jaws. Int. J. Oral Maxillofac. Surg. 39(3), 251-255 (2010).
161. Wilde F, Heufelder M, Winter K et al. The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 111(2), 153-163 (2011).
162. Vescovi P, Manfredi M, Merigo E et al. Early surgical laser-assisted management of bisphosphonate-related osteonecrosis of the jaws (BRONJ): a retrospective analysis of 101 treated sites with long-term follow-up. Photomed. Laser Surg. 30(1), 5-13 (2012).
163. Voss PJ, Joshi Oshero J, Kovalova-Muller A et al. Surgical treatment of bisphosphonate-associated osteonecrosis of the jaw: technical report and follow up of 21 patients. J. Craniomaxillofac. Surg. 40(8), 719-725 (2012).
164. Jabbour Z, El-Hakim M, Mesbah-Ardakani P, Henderson JE, Albuquerque R Jr. The outcomes of conservative and surgical treatment of stage 2 bisphosphonate-related osteonecrosis of the jaws: a case series. Int. J. Oral Maxillofac. Surg. 41(11), 1404-1409 (2012).
165. Ungari C, Quarato D, Gennaro P et al. A retrospective analysis of the headache associated with temporomandibular joint disorder. Eur. Rev. Med. Pharmacol. Sci. 16(13), 1878-1881 (2012).
166. Dimitrakopoulos I, Magopoulos C, Katopodi T. Mandibular osteomyelitis in a patient with pyknodysostosis: a case report of a 50-year misdiagnosis. J. Oral Maxillofac. Surg. 65(3), 580-585 (2007). (Pubitemid 46329229)
167. Wutzl A, Pohl S, Sulzbacher I et al. Factors influencing surgical treatment of bisphosphonate-related osteonecrosis of the jaws. Head Neck 34(2), 194-200 (2012).
168. Kos M, Kuebler JF, Luczak K, Engelke W. Bisphosphonate-related osteonecrosis of the jaws: a review of 34 cases and evaluation of risk. J. Craniomaxillofac. Surg. 38(4), 255-259 (2010).
169. Pautke C, Bauer F, Otto S et al. Fluorescence-guided bone resection in bisphosphonate-related osteonecrosis of the jaws: first clinical results of a prospective pilot study. J. Oral Maxillofac. Surg. 69(1), 84-91 (2011).
170. Fleisher KE, Doty S, Kottal S et al. Tetracycline-guided debridement and cone beam computed tomography for the treatment of bisphosphonate-related osteonecrosis of the jaw: a technical note. J. Oral Maxillofac. Surg. 66(12), 2646-2653 (2008).
171. Marx RE, Tursun R. Suppurative osteomyelitis, bisphosphonate induced osteonecrosis, osteoradionecrosis: a blinded histopathologic comparison and its implications for the mechanism of each disease. Int. J. Oral Maxillofac. Surg. 41(3), 283-289 (2012).
172. Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 41(3), 318-320 (2007). (Pubitemid 47199147)
173. Lemound J, Eckardt A, Kokemuller H et al. Bisphosphonate-associated osteonecrosis of the mandible: reliable soft tissue reconstruction using a local myofascial flap. Clin. Oral Investig. 16(4), 1143-1152 (2012).
174. Mucke T, Koschinski J, Deppe H et al. Outcome of treatment and parameters influencing recurrence in patients with bisphosphonate-related osteonecrosis of the jaws. J. Cancer Res. Clin. Oncol. 137(5), 907-913 (2011).
175. Vescovi P, Manfredi M, Merigo E et al. Surgical approach with Er:YAG laser on osteonecrosis of the jaws (ONJ) in patients under bisphosphonate therapy (BPT). Lasers Med. Sci. 25(1), 101-113 (2010).
176. Curi MM, Cossolin GS, Koga DH et al. Bisphosphonate-related osteonecrosis of the jaws-an initial case series report of treatment combining partial bone resection and autologous platelet-rich plasma. J. Oral Maxillofac. Surg. 69(9), 2465-2472 (2011).
177. Ferlito S, Puzzo S, Palermo F, Verzi P. Treatment of bisphosphonate- related osteonecrosis of the jaws: presentation of a protocol and an observational longitudinal study of an Italian series of cases. Br. J. Oral Maxillofac. Surg. 50(5), 425-429 (2012).